The Two Companies Inside Optimi Health

Optimi Health, a maker of psilocybin and MDMA capsules in a Health Canada-licensed facility in British Columbia, announced last week that it would sponsor a Phase 2 trial of psilocybin-assisted therapy for major depressive disorder: up to 200 patients across Canada, a single supervised dose, data it would "exclusively" own. The stock rose about 3% on the day of the announcement.

That is a mild response to what the company calls its "largest clinical commitment" to date. The restraint is the market quietly answering the real question. It isn't whether psilocybin treats depression — too big a question, too far off to price. It's which Optimi is making this bet. There are two companies with that name.

The one that exists today is a supplier. It manufactures finished GMP-grade psilocybin and MDMA capsules and sells them to authorized psychiatrists in Australia, where psilocybin and MDMA are legally prescribable, and to Canadian physicians through Health Canada's Special Access Program. This is close to the thing a product company should be doing: real doctors writing real prescriptions for real capsules.

The numbers pull at that story. For the nine months through June 30, revenue was C$239,700, down from C$490,330 a year earlier. Optimi attributes the decline to earlier Australian shipments being one-time stocking orders now working through the channel as sell-through. That is real pull without yet being a repeatable business. Demand in a young market arrives in lumps.

Now the second company. By sponsoring the trial instead of just selling product into someone else's study, Optimi takes on the cost, the design, and the data. The CEO calls the 200-patient study the largest clinical commitment in the company's history and among the largest trials of naturally derived psilocybin so far. The logic is vertical integration: don't be a commodity ingredient supplier whose value lives in someone else's evidence; own the molecule and the data, and use them to move toward registration. His framing — that few companies in this sector are commercial today while advancing their own clinical development — treats the two halves as reinforcing each other.

Here is what pulls against that. The commercial half brought in C$240,000 in nine months. It burned about C$3.8 million of operating cash in that window and lost C$5.7 million, more than double the prior year. The working capital cushion Optimi now points to, roughly C$5.9 million, was built largely by a Nasdaq listing earlier this year that raised about US$15 million for 2.4 million shares.

And the same weeks that produced the "comfortably fund it from cash" assurance produced a filing that reads differently. Optimi set up a US$100 million equity line with an investor named Seven Knots, registered roughly 21.9 million resale shares under it — equal to about 383% of the company's currently outstanding stock — and priced draws at 97% of the lower of the day's low or the volume-weighted average. The prospectus carries going-concern language. An equity line that resells shares at a discount to weak prices is not spare capital. It is a standing ceiling on the stock and a claim on the downside.

Put those two facts next to each other. A 200-patient psychedelic trial — screening, therapy sessions, months of follow-up — is not a cheap undertaking, and this one has not started dosing yet. Optimi says it can fund it from cash on hand. The company saying that generates no meaningful revenue, burns C$3.8 million of operating cash every nine months, and has armed itself with a dilution facility worth many times its market value. One of those statements is load-bearing; the other is a hope.

I can't tell you which Optimi wins that fight. I can tell you how to find out, and it isn't by reading the depression headlines. Watch the share count. Having shares equal to 383% of the float registered for resale means the clinical ambition, if it needs the facility's money, gets paid for in dilution at a discount. And watch whether the Australian business starts compounding — repeat shipments, growing quarters — because that is the one place real, paying demand has shown up at all.

An investor who believes the hybrid story is really buying the development half. An investor who believes the supplier story is buying the cash half. Those are different bets with different odds and different ways to lose. The announcement asks you to treat them as the same bet. The balance sheet says they probably aren't.